drugset / Trial / NCT02805725
Targeting Microenvironment and Cellular Immunity in Sarcomas Weekly Trabectedin Combined With Metronomic Cyclophosphamide
Non-randomizedSingle-groupOpen-labelTreatment
Summary
Assessment of the efficacy and safety of trabectedin and metronomic cyclophosphamide (CP) in patients with advanced pretreated soft-tissue sarcomas, once the Maximum Tolerated Dose (MTD) have been determined (phase I trial).
Timeline
- Start
- 2015-12
- Primary completion
- 2020-04
- Completion
- 2021-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cyclophosphamide | Other / unclassified | 50 mg | — |
| Subject | Trabectedin | Small molecule | 0.3 mg/m2 | Intravenous |
| Subject | Trabectedin | Small molecule | 0.4 mg/m2 | Intravenous |
| Subject | Trabectedin | Small molecule | 0.5 mg/m2 | Intravenous |
| Subject | Trabectedin | Small molecule | 0.6 mg/m2 | Intravenous |